# Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

Study · id `cardio:ct-nct06765265` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06765265](<https://clinicaltrials.gov/study/NCT06765265>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06765265

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 152 participants.

## Technical summary

Registry record NCT06765265. Randomized; no masking; primary purpose supportive care. Start 2025-01-05 (actual); primary completion 2026-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 152 participants (planned count; ClinicalTrials.gov record NCT06765265, source copy `cardio:ctgov-nct06765265-2025-03-11`, retrieved 2026-10-31)
- Started: 2025-01-05 (actual) (ClinicalTrials.gov record NCT06765265, source copy `cardio:ctgov-nct06765265-2025-03-11`, retrieved 2026-10-31)
- Primary completion: 2026-01-01 (anticipated) (ClinicalTrials.gov record NCT06765265, source copy `cardio:ctgov-nct06765265-2025-03-11`, retrieved 2026-10-31)
- Completion: 2026-01-01 (anticipated) (ClinicalTrials.gov record NCT06765265, source copy `cardio:ctgov-nct06765265-2025-03-11`, retrieved 2026-10-31)
- Countries: Pakistan (ClinicalTrials.gov record NCT06765265, source copy `cardio:ctgov-nct06765265-2025-03-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06765265-2025-03-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
- Condition: Acute Coronary Syndromes
- Intervention (Drug): Rosuvastatin 20 mg/day
- Intervention (Drug): Atorvastatin 40 mg
- Lead sponsor: King Edward Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: King Edward Medical University (`cardio:org-king-edward-medical-university`)

## Provenance

Content hash: e92a19c024aaa95f93358b1137f47ddc052555aff5958cf363b575831a307d7d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
